AstraZeneca PLC said late-stage trials for the Covid-19 vaccine it is developing with the University of Oxford are on track to produce results “later this year,” with a potential rollout soon after, subject to regulatory approval.
Timing of the much-anticipated results depends on community infection rates around the world, with around 23,000 volunteers now enrolled in the clinical trials in the U.S., the U.K., Brazil and South Africa, the British drugmaker said Thursday as it reported third-quarter earnings.
The…
This post first appeared on wsj.com
